Palvella Therapeutics, Inc. PVLA R2K
Healthcare · Biotechnology · United States
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of angiokeratomas and other mTOR-driven skin diseases; and QTORIN pitavastatin for the treatment of disseminated superficial actinic porokeratosis. The company is based in Wayne, Pennsylvania.
READ MORE ›$118.46
+390.92% 1Y
Market & Price
Market Cap
$1.70B
Current Price
$118.46
High / Low (52W)
$148.34 / $20.51
Beta
-
Valuation
Stock P/E
-
Industry PE
23.65
Forward P/E
-
PEG Ratio
-
Book Value
$16.23
Price to Book
7.30
P/S
-
EV/EBITDA
-
Dividend Yield
-
Profitability & Returns
ROCE
-74.45%
ROE
-34.25%
ROA
-16.60%
Profit Margin
0.00%
Op Margin
0.00%
EPS (Latest Qtr)
$-1.20
EPS (TTM)
$-4.17
Balance Sheet & Liquidity
Debt/Equity
0.09
Quick Ratio
28.73
Current Ratio
28.88
Debt
$20.38M
Total Assets
$59.56M
Current Assets
$58.99M
Working Capital
$47.64M
Ownership
Promoter Holding
11.65%
Chg in Prom Hold
-
FII / Inst Holding
95.97%
Chg in FII Hold
-
Financial Snapshot
Enterprise Value
$1.46B
Total Revenue (TTM)
-
EBITDA
-
Free Cash Flow
$-21.60M
Operating Cash Flow
$-29.10M
Shares Outstanding
14.34M
Gross Margin
0.00%
Payout Ratio
0.00%
Growth (CAGR)
Revenue 5Y
-
Profit 5Y
-17.13%
Revenue (YoY)
-
Earnings (YoY)
-
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Earnings shrank at -17.1% CAGR over 5 years.
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | PVLA Palvella Therapeutics, Inc. R2K | 118.46 | - | $1.70B | - | -74.45% | -34.25% | - | -17.13% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Ad space
Quarterly Results
Figures in USD.
| Metric | Sep 2013 | Dec 2013 | Mar 2014 | Jun 2014 | Sep 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.44M | 11.22M | 7.87M | 7.53M | 4.93M | 14.50M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 7.87M | 9.25M | 10.18M | 11.30M | 14.86M |
| Operating Income | -5.76K | -2.20K | -671.22K | -2.77M | -1.84M | -3.70M | -3.53M | -3.88M | -4.38M | -5.80M | -6.18M | -8.01M | -7.89M | -5.18M | -8.14M | -2.24M | -7.80M | -10.68M | -12.23M | -2.91M | -3.86M | -4.66M | -13.00M | -5.06M | -16.76M | -19.01M | -7.46M | -12.33M | -12.17M | -15.51M | 2.06M | -11.81M | -1.76M | -2.91M | - | -7.87M | -9.25M | -10.18M | -11.30M | -14.86M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -6.97M | -8.12M | -9.84M | -10.97M | -13.73M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.22M | 1.35M | 1.51M | 1.74M | 2.04M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -8.19M | -9.47M | -11.35M | -12.71M | -15.77M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Net Income | -5.76K | -2.20K | -779.90K | -2.88M | -2.02M | -3.70M | -3.53M | -3.92M | -4.16M | -5.88M | -6.20M | -7.99M | -10.09M | -7.06M | -8.71M | -203.00K | -6.15M | -10.35M | -11.76M | -2.59M | -3.60M | -4.95M | -14.28M | -4.17M | -15.50M | -16.54M | -5.10M | -10.34M | -9.74M | -13.18M | 3.98M | -10.75M | -2.54M | -4.17M | - | -8.19M | -9.47M | -11.35M | -12.71M | -15.77M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.09 | -0.26 | -0.07 | -0.25 | -0.24 | -0.07 | -0.14 | - | - | 3.62 | -8.70 | -1.54 | -2.47 | -0.62 | -0.74 | -0.86 | -1.03 | - | -1.20 |
| R&D Expense | - | - | 1.22M | 1.12M | 926.60K | 1.52M | 1.73M | 2.05M | 3.66M | 4.50M | 4.62M | 5.36M | 5.40M | 6.26M | 7.94M | 9.15M | 11.40M | 14.30M | 13.37M | 13.21M | 12.76M | 11.33M | 11.82M | 16.56M | 15.80M | 18.94M | 14.07M | 11.95M | 13.59M | 13.42M | 14.33M | 9.60M | 984.00K | 1.44M | 3.18M | 4.07M | 5.12M | 6.53M | - | 9.33M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2013 | Jun 2014 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | 27.25M | 43.65M | - | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | 18.04M | 11.87M | 14.10M | 38.60M |
| Operating Income | 553.83K | -15.71K | -7.20M | -13.68M | -22.76M | -14.59M | -30.83M | -27.16M | -33.92M | -51.83M | -18.04M | -11.87M | -14.10M | -38.60M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | -18.04M | 18.69M | -13.12M | -35.90M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | 0 | 4.32M | 5.82M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | -28.58M | 18.69M | -17.43M | -41.72M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | -1.03M | 0 | 0 | 0 |
| Net Income | 66.20K | -15.71K | -9.85M | -14.06M | -22.80M | -17.65M | -26.75M | -25.47M | -37.23M | -45.74M | -27.55M | 18.69M | -17.43M | -41.72M |
| Diluted EPS | - | - | - | - | - | - | - | - | -0.68 | -0.71 | -2.46 | 1.60 | -7.83 | -3.71 |
| R&D Expense | 9.41M | - | 5.60M | 8.24M | 19.70M | 22.29M | 41.49M | 55.00M | 46.53M | 66.66M | 52.98M | 8.79M | 8.15M | 22.84M |
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | - |
Compounded Profit Growth
| 5 Years: | -17.13% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +390.92% |
| 6 Months: | +24.87% |
| 3 Months: | -12.26% |
| 1 Month: | -3.25% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2012 | May 2013 | Jun 2013 | Dec 2013 | Jun 2014 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Jan 2019 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 5.20K | 7.28M | 11.14K | 21.86M | 33.95M | 35.06M | 103.88M | 141.34M | 143.18M | 141.10M | 105.01M | 153.56M | 16.52M | 7.55M | 88.23M | 59.56M |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 16.52M | 7.55M | 88.23M | 58.99M |
| Cash & Equivalents | 6.33M | 0 | 5.20K | 3.69M | 11.14K | 18.47M | 29.35M | 29.36M | 37.88M | 74.87M | - | 62.26M | 70.44M | 117.76M | 16.05M | 7.35M | 83.60M | 57.98M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 358.00K | 0 |
| Total Liabilities | - | - | 474 | 6.69M | 1.12K | 3.85M | 2.82M | 9.84M | 92.35M | 101.41M | 104.88M | 89.75M | 73.98M | 102.81M | 39.70M | 11.43M | 25.63M | 31.58M |
| Current Liabilities | - | - | - | 1.77M | - | 3.52M | 2.80M | 8.38M | 45.77M | 48.08M | - | 27.00M | 22.14M | 50.56M | 5.78M | 2.36M | 12.04M | 11.34M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 633.00K |
| Total Equity | 495.70K | - | - | 585.01K | - | 18.01M | 31.13M | 25.23M | 11.52M | 39.94M | 38.29M | 51.35M | 31.03M | 50.76M | -23.17M | -3.88M | 62.61M | 27.98M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 11.22M | 11.01M | 11.01M | 12.38M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2013 | Jun 2014 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | -15.06K | - | - | - | 49.75M | -1.07M | -52.47M | -45.90M | -7.66M | -14.84M | -13.70M | -10.84M | -25.01M |
| Investing Cash Flow | - | - | - | - | - | -45.88M | -8.88M | 9.84M | 39.21M | -949.00K | - | - | - | - |
| Financing Cash Flow | - | 21.00K | - | - | - | 4.09M | 48.51M | 32.17M | 10.12M | 59.13M | 9.57M | 5.00M | 87.09M | -660.00K |
| Capital Expenditure | -49.47K | -0 | -267.41K | -620.75K | -560.00K | -1.95M | -1.70M | -2.46M | -2.73M | -949.00K | - | - | - | - |
| Free Cash Flow | - | -15.06K | - | - | - | 47.80M | -2.76M | -54.93M | -48.62M | -8.61M | -14.84M | -13.70M | -10.84M | -25.01M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | -5.27M | -8.70M | 76.25M | -25.67M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2013 | Jun 2014 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | -113.1% | -62.2% | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - | -98.2% | -58.4% | - | - | - | - | - | - |
| ROE % | 11.3% | - | -54.7% | -45.2% | -90.4% | -153.2% | -67.0% | -49.6% | -120.0% | -90.1% | 118.9% | -481.7% | -27.8% | -149.1% |
| ROCE % | 10.1% | - | -39.2% | -43.9% | -85.3% | -25.1% | -33.1% | -23.8% | -40.9% | -50.3% | -167.9% | -228.8% | -18.5% | -80.1% |
Shareholding Pattern
Insiders
11.65%
Institutions
95.97%
Public Float
108.62%
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Suvretta Capital Management, LLC | 8.04% | 1.15M | $136.64M |
| 2 | First Light Asset Management, LLC | 6.84% | 980.76K | $116.18M |
| 3 | BVF Inc. | 6.70% | 960.99K | $113.84M |
| 4 | Frazier Life Sciences Management, L.P. | 6.15% | 882.40K | $104.53M |
| 5 | Blackrock Inc. | 4.79% | 686.85K | $81.36M |
| 6 | Jennison Associates LLC | 4.47% | 640.61K | $75.89M |
| 7 | Vanguard Capital Management LLC | 3.33% | 477.29K | $56.54M |
| 8 | State Street Corporation | 3.20% | 459.00K | $54.37M |
| 9 | Federated Hermes, Inc. | 3.02% | 433.01K | $51.29M |
| 10 | Price (T.Rowe) Associates Inc | 2.81% | 402.56K | $47.69M |
Analyst View
Loading analyst coverage…
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for PVLA
No recent headlines available.